Paraoxonase 1 and Chronic Obstructive Pulmonary Disease: A Meta-Analysis

Area of Science:

• Pulmonary Medicine
• Biochemistry
• Oxidative Stress Research

Background:

• Oxidative stress significantly contributes to chronic obstructive pulmonary disease (COPD) pathophysiology.
• Paraoxonase 1 (PON1), an antioxidant enzyme, is a potential COPD biomarker, but existing data on its activity in COPD patients are conflicting.
• Clarifying PON1 status in COPD is crucial for understanding disease mechanisms and potential therapeutic targets.

Purpose of the Study:

• To conduct a meta-analysis to definitively assess paraoxonase 1 (PON1) activity in patients with chronic obstructive pulmonary disease (COPD).
• To resolve inconsistencies in previous studies regarding PON1 levels in COPD.
• To investigate potential differences in PON1 activity based on COPD severity.

Main Methods:

• A systematic literature search was performed across MEDLINE, Embase, and CENTRAL databases for studies published before October 2021.
• Included studies focused on PON1 activity (paraoxonase and arylesterase) in stable COPD patients compared to healthy controls.
• Random-effects models were employed for the meta-analysis of data from twelve identified studies.

Main Results:

• Patients with COPD exhibited significantly lower paraoxonase activity (SMD -0.77) and arylesterase activity (SMD -1.15) compared to healthy controls.
• Subgroup analysis revealed lower paraoxonase activity in studies of non-severe COPD (SMD -1.42) but slightly higher activity in studies of severe COPD (SMD 0.33).
• Arylesterase activity demonstrated a similar trend across different COPD severities.

Conclusions:

• Overall PON1 activity is diminished in COPD patients, suggesting a compromised antioxidant defense system.
• The findings highlight the role of impaired PON1 function in COPD pathogenesis.
• Further research is recommended to explore the clinical implications and therapeutic potential of PON1 in COPD management.